Arca
Skip to content
Tools
Tools

L: RNA-directed RNA polymerase L

Protein in Zaire ebolavirus (strain Mayinga-76) (ZEBOV) (Zaire Ebola virus) that 2 drugs act on.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on L, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved1

  • Remdesivir

Phase 30

    Phase 21

    • Galidesivir

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      RemdesivirBoxed warningApprovedGilead SciencesSmall moleculeInhibitorRNA-directed RNA polymerase L inhibitor19
      GalidesivirPhase 2BioCryst PharmaceuticalsSmall moleculeInhibitorRNA-directed RNA polymerase L inhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
      OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 PatientsRemdesivirPhase 2RecruitingCalmy AlexandraFeb 12, 2026
      Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant PatientsRemdesivirPhase 2RecruitingFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaSep 29, 2025
      A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely ImmunocompromisedRemdesivirPhase 3RecruitingPfizerJun 10, 2025
      Safety, Pharmacokinetics, and Antiviral Activity of Remdesivir (VEKLURY®) in Hospitalized Children With RSVRemdesivirPhase 2RecruitingPENTA FoundationMar 13, 2025
      Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised IndividualsRemdesivirPhase 2RecruitingFred Hutchinson Cancer CenterFeb 10, 2025
      Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical TrialRemdesivirPhase 4RecruitingMount Sinai Hospital, CanadaJan 24, 2025
      Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised PatientsRemdesivirNot applicableNot yet recruitingNational Taiwan University HospitalSep 24, 2024
      Adaptive Dengue Antiviral Platform TrialRemdesivirPhase 2RecruitingOxford University Clinical Research Unit, VietnamAug 13, 2024

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4303062, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.